Upgrade to SI Premium - Free Trial

William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'

December 3, 2024 7:06 AM
William Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).The analyst comments "On Monday, December 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Momentum Movers Trader Talk

Next Articles